More Arikace-treated patients reported adverse events in the study compared to patients treated with TOBI. Eleven Arikace patients reported severe side effects compared to six patients on TOBI.
What a joke you are,insmredbird, I mean insmdodobird-either way your desperation is so sad it`s funny-You better get posting fool,after all at .25 a post you have a lot of posting to do. Lie away you idiot,your the new joke of the board.
Sentiment: Strong Buy
five actually, not six, but delighted to note that Novartis is here paying SO much attention to the trial.
$5bn if you want to buy us outright tomorrow, but Insmed is not for sale - too late, but thanks again for all the attention.
Funny, but I was about to start a thread "the new bashers are working for big pharma." And probably some of the more senior naysayers. Several large pharmas are watching and listening, and those interested in making a serious bid will continue to make every effort to hold the pps in check. Only one problem: WL knows the rules of engagement and will not surrender to the lions at the gate. Now that endpoints were met in P3 CF, the heat will increase. It is very unlikely that EU says NO. Even one of the panel members said yesterday that Arikace qualifies for the regimen for CF patients. Another Dr. said she would not hesitate to prescribe. And these doctors are some of the top specialist for lung infections. Now imagine if Phase II for NTM produces solid results and FDA considers fast track. This board will light up like the Empire State Building and the offers will be in the billions.
Well, *Cramer* pumps Novartis any chance he gets and coincidently (?), The Street had a negative article out within a nanosecond of the data release slides yesterday. I'm sure they were grateful for our 3 day heads-up PR on Friday as well...